Vaxcyte (PCVX) Accumulated Expenses (2019 - 2026)

Vaxcyte (PCVX) has reported Accumulated Expenses for 8 consecutive years, with $30.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 16.15% year-over-year to $30.2 million; the TTM figure through Mar 2026 stood at $30.2 million (up 16.15% YoY), while the FY2025 annual figure was $31.1 million, up 6.68% from the prior year.
• Accumulated Expenses fell to $30.2 million in Q1 2026 per PCVX's latest filing, from $31.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $54.2 million in Q1 2024 and bottomed at $4.4 million in Q2 2023.
• Historically, Accumulated Expenses has averaged $19.6 million across 5 years, with a median of $15.4 million in 2022.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 602.2% — and 2023, when it tumbled 55.37%.
• Vaxcyte's Accumulated Expenses stood at $15.4 million in 2022, then declined by 28.09% to $11.1 million in 2023, then soared by 163.41% to $29.1 million in 2024, then gained by 6.68% to $31.1 million in 2025, then declined by 2.64% to $30.2 million in 2026.
• Business Quant data shows PCVX's Accumulated Expenses at $30.2 million in Q1 2026, $31.1 million in Q4 2025, and $16.8 million in Q3 2025.